Hypercalcemia associated with malignancy is most often mediated by
**Core Concept**
Hypercalcemia associated with malignancy is a paraneoplastic syndrome characterized by elevated serum calcium levels due to the abnormal production of calcium-regulating hormones or factors by cancer cells. This condition can be caused by various types of cancers, including breast, lung, kidney, and multiple myeloma.
**Why the Correct Answer is Right**
The most common mechanism of hypercalcemia in malignancy is through the production of parathyroid hormone-related protein (PTHrP) by cancer cells. PTHrP mimics the action of parathyroid hormone (PTH), which is a hormone produced by the parathyroid glands that regulates calcium levels in the blood. PTHrP stimulates osteoclasts to break down bone, releasing calcium into the bloodstream. This leads to an increase in serum calcium levels, resulting in hypercalcemia. Other mechanisms, such as the production of 1,25-dihydroxyvitamin D by cancer cells, can also contribute to hypercalcemia.
**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because while vitamin D is involved in calcium homeostasis, its primary role is in the absorption of calcium from the gut, not in the direct regulation of serum calcium levels.
* **Option B:** This option is incorrect because while parathyroid hormone (PTH) is a key regulator of calcium levels, its primary action is to increase calcium levels by stimulating bone resorption, but it is not the primary mechanism of hypercalcemia in malignancy.
* **Option D:** This option is incorrect because while bone metastases can contribute to hypercalcemia, they are not the primary mechanism of hypercalcemia in malignancy.
**Clinical Pearl / High-Yield Fact**
The most common cause of hypercalcemia in malignancy is the production of PTHrP by cancer cells, which can be detected using immunohistochemical staining. This is an important diagnostic clue for physicians to consider when evaluating patients with cancer and hypercalcemia.
**Correct Answer: C. PTHrP**